Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?
- 1 July 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 30 (7) , 533-541
- https://doi.org/10.1097/mnm.0b013e32832b79bc
Abstract
Objectives The first objective of this study was to evaluate the radiological impact on relatives and the environment because of outpatient treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (I-131)NaI. The second objective was to determine, analyze, and evaluate whole-body radiation dose to caregivers, the production of contaminated solid waste, and the potentiality of radiation dose and surface contamination existing inside patients' households. Methods Twenty patients were treated on an outpatient basis, taking into consideration their acceptable living conditions, interests, and willingness to comply with medical and radiation-safety guidelines. The caregivers themselves, as well as the potentiality of the radiation dose inside patients' residences, were monitored with a thermo-luminescence dosimeter. Surface contamination and contaminated solid wastes were identified and measured by using a Geiger-Muller detector. Results and discussion Twenty-six monitored individuals received accumulated effective radiation doses of less than 1.0 mSv, and only one 2.8 mSv, throughout the 7 days of measurement. The maximum registered value for the potential of radiation dose inside all living areas was 1.30 mSv. The monitored surface contamination inside patients' dwellings showed a mean value of 4.2 Bq/cm(2) for all surfaces found to be contaminated. A total of 2.5l of contaminated solid waste was generated by the patients with 3.33 MBq of all estimated activity. Conclusion This study revealed that the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (I-131)NaI, on an outpatient basis, can be safe when overseen by qualified professionals and with an adapted radiation-protection guideline. Even considering the radioiodine activity level and the dosimetric methodology applied here, negligible human exposure and a nonmeasurable radiological impact to the human environment were found. Nucl Med Commun 30:533-541 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.Keywords
This publication has 12 references indexed in Scilit:
- Radiation exposure for ‘caregivers’ during high-dose outpatient radioiodine therapyRadiation Protection Dosimetry, 2007
- EVALUATION OF THE POTENTIAL ABSORBED DOSES FROM PATIENTS BASED ON WHOLE-BODY 131I CLEARANCE IN THYROID CANCER THERAPYHealth Physics, 2006
- Radiation exposure to family members of patients with thyrotoxicosis treated with iodine-131European Journal of Nuclear Medicine and Molecular Imaging, 2005
- Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131IRadiation Protection Dosimetry, 2005
- Potential third-party radiation exposure from outpatients treated with I131 for hyperthyroidismMedical Physics, 2004
- Current Approaches to Primary Therapy for Papillary and Follicular Thyroid CancerJournal of Clinical Endocrinology & Metabolism, 2001
- Radiation Exposure From Outpatient Radioactive Iodine (131I) Therapy for Thyroid CarcinomaPublished by American Medical Association (AMA) ,2000
- Radioiodine ( 131 I) treatment of hyperthyroidism: radiation protection and quality assuranceEuropean Journal of Nuclear Medicine and Molecular Imaging, 1999
- Behavior of Na 131I and Meta (131I) Iodobenzylguanidine (MIBG) in Municipal SewerageHealth Physics, 1997
- Iodine-131 levels in sludge and treated municipal wastewaters near a large medical complex.American Journal of Public Health, 1981